Latest News & Features
Americas
Corporate legal teams can embrace the AI revolution by encouraging experimentation and managing risks proactively, according to a recent panel featuring leading pharma counsel. 10 December 2024
Americas
As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen. 5 December 2024
Americas
Jury finds medical device company misappropriated secrets covering Insulet’s Omnipod l Insulet “extremely pleased” with verdict l Federal circuit overturned ban on EOFlow’s product in June. 5 December 2024
Americas
European Supplementary Protection Certificates (SPCs) are very different to US PTEs in several key respects. In this seminar, we'll run through strategies to secure maximal protection for approved pharmaceutical & biologic products in Europe. 4 December 2024
Americas
Korean pharmaceutical, biotech, and life sciences companies are actively expanding globally, leading to more complex and multifaceted IP strategies than in the past. 4 December 2024
Americas
German biotech asks federal judge to reject Amgen’s efforts to narrow scope of a key patent in ongoing dispute | Patent relates to Lindis' cancer immunotherapy treatment | Lindis calls on court to uphold the broader interpretation and claims Amgen’s attempt to narrow is inconsistent with the patent's history. 3 December 2024
Europe
One-day event in London brings in-house counsel and private practitioners together | First sessions to kick off the day covered European Patent Office procedures, and in-house views on how the UPC is faring. 3 December 2024
Careers
Former EIP partner joins IP and technology practice | New London hire is known for high-stakes, cross-border patent litigation. 3 December 2024
Americas
The dynamic landscape of patent law is continually influenced by evolving regulations and legal decisions, and one of the key areas at the forefront of these changes is the Patent Trial and Appeal Board (PTAB). 2 December 2024
Americas
New England Biolab contends plaintiff’s patents are invalid and cover “unpatentable natural processes”| Biomodal had accused rival of infringing several patents covering methods to detect and modify DNA methylatian—a key part of epigenetic research 28 November 2024